Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Composition for adjuvant containing poly-gamma-glutamic acid

A technology of synthetic and glutamic acid, applied in the local field, can solve problems such as being unsuitable for mass production, difficult to decompose vaccines in the body, and easily affected in quality

Active Publication Date: 2008-04-16
BIOLEADERS CORP +1
View PDF0 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] Currently, aluminum species are almost the only adjuvants approved for use in human patients, but have the disadvantage of relatively low immune-enhancing effects compared to other adjuvants
Moreover, aluminum species enhance immune responses mainly by stimulating Th2 immune responses during immune responses (Audibert and Lise, Immunol. Today, 14:281-284, 1993), so its use is limited to those requiring enhanced cytotoxic T cell immune responses. Adjuvants required for vaccines
In addition, vaccines containing aluminum adjuvants have the disadvantage of being difficult to break down in the body and difficult to preserve by lyophilization due to its stickiness, its precipitation properties when aluminum is frozen
In addition, aluminum compounds (aluminum sulfate, aluminum hydroxide, aluminum phosphate, etc.) can be used in human vaccines, but have the disadvantages that the quality is easily affected and easily changed during the production process, and because the purification operation is difficult, it is not suitable for mass production

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Composition for adjuvant containing poly-gamma-glutamic acid
  • Composition for adjuvant containing poly-gamma-glutamic acid
  • Composition for adjuvant containing poly-gamma-glutamic acid

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0031] Example 1. Production of poly-γ-glutamic acid

[0032] Containing 3L basic medium (GS medium containing 5% L-glutamate, 5% glucose, 1% (NH 4 ) 2 SO 4 , 0.27% KH 2 PO 4 , 0.42% Na 2 HPO 4 .12H 2 O, 0.05% NaCl, 0.3% MgSO 4 .7H 2 (0, 1ml / L vitamin solution, pH 6.8) was inoculated with 1% Bacillus subtilis var.chungkookjang (KCTC 0697BP) culture solution in a 5L fermenter, and cultivated at a stirring speed of 150rpm, an air blowing rate of 1vvm and 37°C After 72 hours, 2N sulfuric acid solution was added to adjust the pH to 3.0, thereby obtaining a sample solution containing poly-γ-glutamic acid.

[0033] The sample solution was left standing at 4°C for 10 hours to remove polysaccharides present in the fermentation broth, and two volumes of ethanol was added to the fermentation broth, followed by thorough mixing. The mixed solution was left to stand at 4°C for 10 hours, and then centrifuged to obtain a precipitate of poly-γ-glutamic acid. The precipitate was d...

Embodiment 2

[0035] Example 2. Production of antibodies against TGE viral antigens by poly-γ-glutamic acid

[0036] In this example, in order to examine whether the inventive poly-γ-glutamic acid exhibits an immunoenhancing effect specific to a soluble antigen, in the specific immune response to the antibody, in particular, it was examined against the B involved in the production of the antibody. The effect of the humoral immune response elicited by cells. Nucleoprotein (N) of porcine transmissible gastroenteritis virus (TGE), which induces porcine transmissible digestive organ disease, was used as an antigen, and rabbits were used as test animals.

[0037] Rabbits subcutaneously injected with only TGEN antigen (400μg / PBS) were used as a control group, TGEN antigen (400μg / PBS) and poly-γ-glutamic acid with molecular weights of 5kDa, 10kDa, 20kDa, and 50kDa were mixed and injected subcutaneously Rabbits were used as the experimental group.

[0038] Two weeks after the first subcutaneous...

Embodiment 3

[0041] Example 3. Production of antibodies against HBV virus by poly-γ-glutamic acid

[0042] In the examples, in order to examine whether poly-γ-glutamic acid exhibits specific immune enhancement effects (humoral immune response) on other soluble antigens by intraperitoneal injection, Balb / c mice were used as test animals against hepatitis B virus from yeast (HBV) surface antigen test.

[0043] As a control group, 6-week-old Balb / c female mice were injected with purified HBsAg (hepatitis B virus surface antigen) L particle antigen (1 μg / PBS ml) alone in the abdomen, and as a control group, HbsAg L particle antigen (1 μg / PBS ml) ml) and poly-γ-glutamic acid (γ-PGA) with 10 kDa, 50 kDa and 1000 kDa respectively were mixed and injected intraperitoneally. Moreover, with the change of antigen concentration, the control group and HbsAg L particle antigen (0.5 μg / PBS ml) and the molecular weight of 10kDa, 50kDa and A test group in which a poly-γ-glutamic acid mixture of 1000 kDa...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
Login to View More

Abstract

The present invention relates to a composition for an immunopotentiator(adjuvant) containing poly-gamma-glutamic acid and a composition for a vaccine containing the immunopotentiator, and more particularly, to an immunopotentiator containing poly-gamma-glutamic acid capable of enhancing antibody production rate by administering it to an animal together with antigen having low immunogenicity, and a composition for a vaccine containing the immunopotentiator and antigen. The inventive adjuvant has almost no toxicity and side effects, and show high antibody titer even when it is used with antigenhaving poor immunogenicity, so it can be used by adding to medical composition including preventive or curative vaccine for non-contagious chronic diseases as well as cancer, especially prostatic carcinoma, colon carcinoma, lung cancer, breast cancer, ovarian cancer, head and neck cancer, pudendum cancer, bladder cancer, brain tumor and glioma.

Description

technical field [0001] The present invention relates to a composition containing poly-γ-glutamic acid used as an immunopotentiator (adjuvant) and a composition containing the immunopotentiator used as a vaccine, more particularly, to a composition containing poly-γ - An immunopotentiator of glutamic acid, which can enhance antibody production rate by administering to animals together with an antigen having low immunogenicity, and a composition for use as a vaccine containing the immunopotentiator and antigen . Background technique [0002] So far, many studies have been conducted on subunit vaccines using antigenic proteins or antigenic peptides, DNA vaccines using antigenic DNA, and various recombinant vaccines. These vaccine candidate substances have the advantage of having few side effects, but have the disadvantage of weak immunogenicity. Therefore, the development of immunopotentiators (adjuvants) that effectively enhance the immune response of vaccine candidate subst...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/39A61K47/30
CPCA61K39/39A61K2039/55516A61P1/04A61P11/00A61P13/08A61P13/10A61P15/00A61P25/00A61P35/00A61P37/04A61P43/00A61K47/30
Inventor 成文喜金哲仲夫夏玲洪承杓李宗洙金智渊
Owner BIOLEADERS CORP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com